Resources
About Us
Home Report
Store
RWE Oncology Market
RWE Oncology Market by Component (Real-world Datasets, RWE Consulting & Analytics Services), Application (Drug Development & Approvals, Market Access, Post-market Surveillance), End User & Geography – Global Forecast to 2035
Report ID:MRHC - 104590 Pages: 201 May-2025 Formats*: PDF Category: Healthcare Delivery: 24 to 48 HoursThe global RWE oncology market was valued at $789 million in 2024. This market is expected to reach $3.51 billion by 2035, growing from an estimated $893 million in 2025, at a CAGR of 14.7% during the forecast period of 2025–2035.
Report Overview
This report examines the global market for real-world evidence (RWE) oncology solutions, focusing on how providers are meeting the increasing need for evidence-driven cancer care, value-based healthcare approaches, and regulatory mandates for post-market surveillance. It offers a strategic analysis of market trends, projections through 2035, and a comprehensive evaluation of the competitive environment across global, regional, and country-specific levels.
Key Market Drivers & Trends
The RWE oncology solutions market is primarily driven by the growing demand for real-world evidence in drug development, increasing focus on value-based healthcare, rising cancer incidence and prevalence globally, regulatory support for RWE in healthcare decision-making, and advancements in data analytics and AI technologies. The shift towards patient-centric healthcare models, adoption of cloud-based RWE platforms, integration of genomic and molecular data, and real-time data collection and analysis are reshaping the industry. Additionally, integration with precision medicine initiatives and development of AI-powered analytics solutions are gaining significant traction, especially in developed markets with advanced healthcare infrastructure.
Key Challenges
Although the RWE oncology solutions market holds substantial growth potential, it encounters several challenges such as data privacy and security concerns, lack of standardization in data collection, and high implementation and maintenance costs. Furthermore, hurdles like limited interoperability between healthcare systems, regulatory compliance across different regions, data quality and completeness issues, and integration of disparate data sources pose significant barriers that could hinder market adoption in different parts of the world.
Growth Opportunities
The RWE oncology solutions market presents numerous avenues for high growth. Expansion in emerging markets offers substantial opportunities for market players looking to reach new customer bases. Integration with precision medicine initiatives provides another key opportunity, enhancing the accessibility of personalized cancer care. Moreover, development of AI-powered analytics solutions and partnerships between healthcare stakeholders are generating new revenue streams for solution providers as organizations seek evidence-based alternatives to traditional healthcare decision-making methods.
Market Segmentation Highlights
By Component
The Datasets segment is expected to hold the largest share of the overall RWE oncology solutions market in 2025, driven by increasing demand for comprehensive cancer data across the healthcare ecosystem. This segment includes disparate datasets (EMR/EHR/clinical data, claims & billing data, pharmacy data, cancer registries, and other disparate datasets) and integrated datasets. However, the Consulting Services segment is expected to experience significant growth during the forecast period, driven by the growing need for expertise in RWE study design, regulatory guidance, and data interpretation services.
By Application
The Market Access & Reimbursement/Coverage Decisions segment is expected to hold the largest share of the overall RWE oncology solutions market in 2025, driven by payers' increasing reliance on RWE for value-based healthcare decisions, coverage determinations, and the broad demand from insurance companies, government programs, and health systems for real-world cost-effectiveness data. However, the Drug Development & Approvals segment is expected to experience significant growth during the forecast period, driven by increasing regulatory acceptance of RWE in drug approval processes and growing pharmaceutical investment in oncology research.
By End User
The Pharmaceutical, Biotechnology, and Medical Device Companies segment is expected to hold the largest share of the overall RWE oncology solutions market in 2025, due to their substantial investment in oncology R&D and regulatory requirements for post-market surveillance. However, the Healthcare Payers segment is expected to experience notable growth during the forecast period, driven by increasing adoption of value-based care models and the need for cost-effectiveness evidence in coverage decisions.
By Geography
North America is expected to hold the largest share of the global RWE oncology solutions market in 2025, driven by advanced healthcare infrastructure, strong regulatory support for RWE, well-established pharmaceutical industry, and favorable reimbursement policies.
Additionally, high cancer incidence rates and mature data analytics capabilities contribute significantly to market dominance. Europe follows as a significant market, bolstered by stringent regulatory requirements and increasing adoption of digital health technologies. However, Asia-Pacific is witnessing the fastest growth rate during the forecast period, primarily driven by rising cancer burden, expanding healthcare infrastructure, growing pharmaceutical investments, and increasing awareness about precision medicine approaches.
Competitive Landscape
The global RWE oncology solutions market is characterized by a diverse competitive environment, comprising established healthcare data analytics companies, pharmaceutical service providers, technology giants, and specialized oncology data solution providers, each adopting unique approaches to advancing RWE capabilities.
Within this landscape, solution providers are segmented into industry leaders, market differentiators, vanguards, and contemporary stalwarts, with each group implementing distinct strategies to sustain their competitive edge. Leading companies are prioritizing integrated platforms that merge comprehensive oncology datasets with advanced analytics capabilities, while also addressing data standardization challenges specific to various regions.
The key players operating in the global RWE oncology solutions market include IQVIA Holdings Inc., Veracyte Inc., Flatiron Health Inc., IBM Corporation, Oracle Corporation, SAS Institute Inc., ICON plc, Parexel International Corporation, Syneos Health Inc., Cognizant Technology Solutions Corporation, UnitedHealth Group Incorporated, Anthem Inc., Clinigen Group plc, PerkinElmer Inc., and Tempus Labs Inc., among others.
RWE Oncology Solutions Market Report Summary
|
Particulars |
Details |
|
Number of Pages |
201 |
|
Format |
PDF & Excel |
|
Forecast Period |
2025-2035 |
|
Base Year |
2024 |
|
CAGR (Value) |
14.7% |
|
Market Size (Value) in 2025 |
USD 893 Million |
|
Market Size (Value) in 2035 |
USD 3.51 Billion |
|
Segments Covered |
Market Assessment By Component
By Application
By End User
|
|
Countries Covered |
North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of Europe), Asia-Pacific (Japan, China, India, South Korea, Taiwan, Singapore, Australia, Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), Middle East & Africa (UAE, Saudi Arabia, South Africa, Rest of MEA) |
|
Key Companies |
IQVIA Holdings Inc., Veracyte Inc., Flatiron Health Inc., IBM Corporation, Oracle Corporation, SAS Institute Inc., ICON plc, Parexel International Corporation, Syneos Health Inc., Cognizant Technology Solutions Corporation, UnitedHealth Group Incorporated, Anthem Inc., Clinigen Group plc, PerkinElmer Inc., and Tempus Labs Inc. |
Key Questions Answered in the Report:
The global RWE oncology solutions market was valued at $789 million in 2024. This market is expected to reach approximately $3.51 billion by 2035, growing from an estimated $893 million in 2025, at a CAGR of 14.7% during the forecast period of 2025-2035.
The global RWE oncology solutions market is expected to grow at a CAGR of 14.7% during the forecast period of 2025-2035.
The global RWE oncology solutions market is expected to reach approximately $3.51 billion by 2035, growing from an estimated $893 million in 2025, at a CAGR of 14.7% during the forecast period of 2025-2035.
The key companies operating in this market include IQVIA Holdings Inc., Veracyte Inc., Flatiron Health Inc., IBM Corporation, Oracle Corporation, SAS Institute Inc., ICON plc, Parexel International Corporation, Syneos Health Inc., Cognizant Technology Solutions Corporation, and others.
Major trends shaping the market include shift towards patient-centric healthcare models, adoption of cloud-based RWE platforms, integration of genomic and molecular data, and real-time data collection and analysis capabilities.
• In 2025, the Datasets segment is expected to hold the largest share of the overall RWE oncology solutions market by component
• Based on application, the Market Access & Reimbursement/Coverage Decisions segment is expected to hold the largest share of the overall market in 2025
• Based on end user, the Pharmaceutical, Biotechnology, and Medical Device Companies segment is expected to hold the largest share of the global market in 2025
North America is expected to hold the largest share of the global RWE oncology solutions market in 2025, driven by advanced healthcare infrastructure, strong regulatory support for RWE, and well-established pharmaceutical industry. Asia-Pacific is witnessing the fastest growth rate during the forecast period.
The growth of this market is driven by growing demand for real-world evidence in drug development, increasing focus on value-based healthcare, rising cancer incidence and prevalence globally, regulatory support for RWE in healthcare decision-making, and advancements in data analytics and AI technologies.
1. Market Definition & Scope
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.1.1. Bottom-up Approach
2.3.1.2. Top-down Approach
2.3.2. Growth Forecast Approach
2.3.3. Assumptions for the Study
3. Executive Summary
3.1. Overview
3.2. Segmental Analysis
3.2.1. RWE Oncology Solutions Market, by Component
3.2.2. RWE Oncology Solutions Market, by Application
3.2.3. RWE Oncology Solutions Market, by End User
3.2.4. RWE Oncology Solutions Market, by Geography
3.3. Competitive Landscape
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Drivers
4.2.1.1. Growing Demand for Real-World Evidence in Drug Development
4.2.1.2. Increasing Focus on Value-Based Healthcare
4.2.1.3. Rising Cancer Incidence and Prevalence Globally
4.2.1.4. Regulatory Support for RWE in Healthcare Decision-Making
4.2.1.5. Advancements in Data Analytics and AI Technologies
4.2.2. Restraints
4.2.2.1. Data Privacy and Security Concerns
4.2.2.2. Lack of Standardization in Data Collection
4.2.2.3. High Implementation and Maintenance Costs
4.2.2.4. Limited Interoperability Between Healthcare Systems
4.2.3. Opportunities
4.2.3.1. Expansion in Emerging Markets
4.2.3.2. Integration with Precision Medicine Initiatives
4.2.3.3. Development of AI-Powered Analytics Solutions
4.2.3.4. Partnerships Between Healthcare Stakeholders
4.2.4. Trends
4.2.4.1. Shift Towards Patient-Centric Healthcare Models
4.2.4.2. Adoption of Cloud-Based RWE Platforms
4.2.4.3. Integration of Genomic and Molecular Data
4.2.4.4. Real-Time Data Collection and Analysis
4.2.5. Challenges
4.2.5.1. Regulatory Compliance Across Different Regions
4.2.5.2. Data Quality and Completeness Issues
4.2.5.3. Integration of Disparate Data Sources
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of Substitutes
4.3.4. Threat of New Entrants
4.3.5. Degree of Competition
4.4. Sustainability Impact on the RWE Oncology Solutions Market
4.4.1. Environmental Sustainability Factors
4.4.1.1. Digital Health Carbon Footprint Reduction
4.4.1.2. Paperless Data Collection and Storage
4.4.2. Market Response to Sustainability Demands
4.4.2.1. Green IT Infrastructure and Cloud Computing
4.4.2.2. Sustainable Healthcare Data Centers
4.4.3. Opportunities from Sustainability Focus
4.4.3.1. Eco-friendly Technology Development
4.4.3.2. Challenges in Sustainable Data Management
5. Regulatory Analysis—Real-world Evidence (RWE) Oncology Solutions Market
5.1. Introduction
5.2. North America
5.3. Europe
5.4. Asia-Pacific
5.4. Latin America
5.4. Middle East & Africa
6. Pricing Models (EMR/Genomic/Integrated Datasets)
6.1. Introduction
6.2. Pay Per Patient Record (Volume-based Pricing)
6.3. Pay Per Usage (Value-based Pricing)
6.4. Annual Subscription
6.5. Tiered Pricing Models
6.6. Custom Enterprise Pricing
7. Global RWE Oncology Solutions Market, by Component
7.1. Introduction
7.2. Datasets
7.2.1. Disparate Datasets
7.2.1.1. EMR/EHR/Clinical Data
7.2.1.2. Claims & Billing Data
7.2.1.3. Pharmacy Data
7.2.1.4. Cancer Registries
7.2.1.5. Other Disparate Datasets
7.2.2. Integrated Datasets
7.3. Consulting Services
8. Global RWE Oncology Solutions Market, by Application
8.1. Introduction
8.2. Drug Development & Approvals
8.3. Market Access & Reimbursement/Coverage Decisions
8.4. Medical Device Development & Approvals
8.5. Post-market Surveillance
8.6. Other Applications
9. Global RWE Oncology Solutions Market, by End User
9.1. Introduction
9.2. Pharmaceutical, Biotechnology, and Medical Device Companies
9.3. Healthcare Payers
9.4. Healthcare Providers
9.5. Other End Users
10. RWE Oncology Solutions Market, by Geography
10.1. Introduction
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. U.K.
10.3.2. Germany
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. Japan
10.4.2. China
10.4.3. India
10.4.4. South Korea
10.4.5. Taiwan
10.4.6. Singapore
10.4.7. Australia
10.4.8. Rest of Asia-Pacific
10.5. Latin America
10.5.1. Brazil
10.5.2. Mexico
10.5.3. Rest of Latin America
10.6. Middle East & Africa
10.6.1. UAE
10.6.2. Saudi Arabia
10.6.3. South Africa
10.6.4. Rest of MEA
11. Competitive Landscape
11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
11.4.1. Industry Leaders
11.4.2. Market Differentiators
11.4.3. Vanguards
11.4.4. Contemporary Stalwarts
11.5. Market Share Analysis, by Key Players, 2024
12. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis)
12.1. IQVIA Holdings Inc.
12.2. Veracyte, Inc.
12.3. Flatiron Health, Inc.
12.4. IBM Corporation
12.5. Oracle Corporation
12.6. SAS Institute Inc.
12.7. ICON plc
12.8. Parexel International Corporation
12.9. Syneos Health, Inc.
12.10. Cognizant Technology Solutions Corporation
12.11. UnitedHealth Group Incorporated
12.12. Anthem, Inc.
12.13. Clinigen Group plc
12.14. PerkinElmer, Inc.
12.15. Tempus Labs, Inc.
13. Appendix
13.1. Available Customization
13.2. Related Reports
LIST OF TABLES
Table 1 Global RWE Oncology Solutions Market Drivers: Impact Analysis (2025–2035)
Table 2 Number of Persons Aged 65 Years or Over, by Region (2019 Vs. 2050)
Table 3 Total Per-study Cost (In USD Million), by Phase and Therapeutic Area
Table 4 Sources of Healthcare Data
Table 5 Global RWE Oncology Market Restraints: Impact Analysis (2025–2035)
Table 6 RWE in Latin American Countries
Table 7 Observed Indicative Prices of Real-World Data by Type (USD Per Patient Record)
Table 8 Global RWE Oncology Solutions Market Size, by Component, 2023-2035 (USD Million)
Table 9 Global Real-world Evidence Oncology Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 10 Real-world Evidence Oncology Datasets Market Size, by Country/Region, 2023-2035 (USD Million)
Table 11 Global RWE Oncology Disparate Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 12 RWE Oncology Disparate Datasets Market Size, by Country/Region, 2023-2035 (USD Million)
Table 13 RWE Oncology EMR/EHR/Clinical Data Market Size, by Country/Region, 2023-2035 (USD Million)
Table 14 RWE Oncology Claims & Billing Data Market Size, by Country/Region, 2023-2035 (USD Million)
Table 15 RWE Oncology Pharmacy Data Market Size, by Country/Region, 2023-2035 (USD Million)
Table 16 RWE Cancer Registries Data Market Size, by Country/Region, 2023-2035 (USD Million)
Table 17 Other RWE Oncology Disparate Datasets Market Size, by Country/Region, 2023-2035 (USD Million)
Table 18 RWE Oncology Integrated Datasets Market Size, by Country/Region, 2023-2035 (USD Million)
Table 19 RWE Oncology Consulting Services Market Size, by Country/Region, 2023-2035 (USD Million)
Table 20 Global RWE Oncology Solutions Market Size, by Application, 2023-2035 (USD Million)
Table 21 Global RWE Oncology Solutions Market Size for Market Access & Reimbursement/Coverage Decisions, by Country/Region, 2023-2035 (USD Million)
Table 22 Oncology: Drugs in the R&D Pipeline
Table 23 Global RWE Oncology Solutions Market Size for Drug Development & Approvals, by Country/Region, 2023-2035 (USD Million)
Table 24 Global RWE Oncology Solutions Market Size for Medical Device Development & Approvals, by Country/Region, 2023-2035 (USD Million)
Table 25 Global RWE Oncology Solutions Market Size for Post-Market Surveillance, by Country/ Region, 2023-2035 (USD Million)
Table 26 Global RWE Oncology Solutions Market Size for Other Applications, by Country/Region, 2023-2035 (USD Million)
Table 27 Global RWE Oncology Solutions Market Size, by End User, 2023-2035 (USD Million)
Table 28 Global RWE Oncology Solutions Market Size for Pharmaceutical, Biotechnology, and Medical Device Companies, by Country / Region, 2023-2035 (USD Million)
Table 29 Global RWE Oncology Market Size for Healthcare Payers, by Country/Region, 2023-2035 (USD Million)
Table 30 Global RWE Oncology Solutions Market Size for Healthcare Providers, by Country/Region, 2023-2035 (USD Million)
Table 31 Global RWE Oncology Market Size for Other End Users, by Country/Region, 2023-2035 (USD Million)
Table 32 Global RWE Oncology Solutions Market Size, by Country/Region, 2023-2035 (USD Million)
Table 33 North America: RWE Oncology Solutions Market Size, by Country, 2023-2035 (USD Million)
Table 34 North America: RWE Oncology Solutions Market Size, by Component, 2023-2035 (USD Million)
Table 35 North America: RWE Oncology Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 36 North America: RWE Oncology Disparate Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 37 North America: RWE Oncology Solutions Market Size, by Application, 2023-2035 (USD Million)
Table 38 North America: RWE Oncology Solutions Market Size, by End User, 2023-2035 (USD Million)
Table 39 U.S.: Estimated Number of New Cancer Cases
Table 40 U.S.: RWE Oncology Solutions Market Size, by Component, 2023-2035 (USD Million)
Table 41 U.S.: RWE Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 42 U.S.: RWE Disparate Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 43 U.S.: RWE Oncology Solutions Market Size, by Application, 2023-2035 (USD Million)
Table 44 U.S.: RWE Solutions Market Size, by End User, 2023-2035 (USD Million)
Table 45 Canada: RWE Oncology Solutions Market Size, by Component, 2023-2035 (USD Million)
Table 46 Canada: RWE Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 47 Canada: RWE Disparate Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 48 Canada: RWE Oncology Solutions Market Size, by Application, 2023-2035 (USD Million)
Table 49 Canada: RWE Oncology Market Size, by End User, 2023-2035 (USD Million)
Table 50 Europe: RWE Oncology Solutions Market Size, by Country, 2023-2035 (USD Million)
Table 51 Europe: RWE Oncology Solutions Market Size, by Component, 2023-2035 (USD Million)
Table 52 Europe: RWE Oncology Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 53 Europe: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 54 Europe: RWE Oncology Solutions Market Size, by Application, 2023-2035 (USD Million)
Table 55 Europe: RWE Oncology Solutions Market Size, by End User, 2023-2035 (USD Million)
Table 56 U.K.: Conferences and Workshops on Real-world Evidence Solutions
Table 57 U.K.: RWE Oncology Solutions Market Size, by Component, 2023-2035 (USD Million)
Table 58 U.K.: RWE Oncology Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 59 U.K.: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 60 U.K.: RWE Oncology Solutions Market Size, by Application, 2023-2035 (USD Million)
Table 61 U.K.: RWE Oncology Solutions Market Size, by End User, 2023-2035 (USD Million)
Table 62 Conferences, Symposia, and Workshops in Germany
Table 63 Germany: RWE Oncology Solutions Market Size, by Component, 2023-2035 (USD Million)
Table 64 Germany: RWE Oncology Solutions Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 65 Germany: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 66 Germany: RWE Oncology Solutions Market Size, by Application, 2023-2035 (USD Million)
Table 67 Germany: RWE Oncology Solutions Market Size, by End User, 2023-2035 (USD Million)
Table 68 France: RWE Oncology Solutions Market Size, by Component, 2023-2035 (USD Million)
Table 69 France: RWE Oncology Solutions Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 70 France: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 71 France: RWE Oncology Solutions Market Size, by Application, 2023-2035 (USD Million)
Table 72 France: RWE Oncology Solutions Market Size, by End User, 2023-2035 (USD Million)
Table 73 Italy: RWE Oncology Solutions Market Size, by Component, 2023-2035 (USD Million)
Table 74 Italy: RWE Oncology Solutions Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 75 Italy: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 76 Italy: RWE Oncology Market Size, by Application, 2023-2035 (USD Million)
Table 77 Italy: RWE Oncology Solutions Market Size, by End User, 2023-2035 (USD Million)
Table 78 Spain: RWE Oncology Market Size, by Component, 2023-2035 (USD Million)
Table 79 Spain: RWE Oncology Solutions Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 80 Spain: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 81 Spain: RWE Oncology Solutions Market Size, by Application, 2023-2035 (USD Million)
Table 82 Spain: RWE Oncology Solutions Market Size, by End User, 2023-2035 (USD Million)
Table 83 RoE: RWE Oncology Solutions Market Size, by Component, 2023-2035 (USD Million)
Table 84 RoE: RWE Oncology Solutions Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 85 RoE: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 86 RoE: RWE Oncology Solutions Market Size, by Application, 2023-2035 (USD Million)
Table 87 RoE: RWE Oncology Solutions Market Size, by End User, 2023-2035 (USD Million)
Table 88 Latin America: RWE Oncology Solutions Market Size, by Component, 2023-2035 (USD Million)
Table 89 Latin America: RWE Oncology Solutions Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 90 Latin America: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 91 Latin America: RWE Oncology Solutions Market Size, by Application, 2023-2035 (USD Million)
Table 92 Latin America: RWE Oncology Solutions Market Size, by End User, 2023-2035 (USD Million)
Table 93 Middle East & Africa: RWE Oncology Solutions Market Size, by Component, 2023-2035 (USD Million)
Table 94 Middle East & Africa: RWE Oncology Solutions Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 95 Middle East & Africa: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2023-2035 (USD Million)
Table 96 Middle East & Africa: RWE Oncology Solutions Market Size, by Application, 2023-2035 (USD Million)
Table 97 Middle East & Africa: RWE Oncology Solutions Market Size, by End User, 2023-2035 (USD Million)
Table 98 Recent Developments, by Company, 2022–2025
LIST OF FIGURES
Figure 1 Key Stakeholders
Figure 2 Research Process
Figure 3 Key Secondary Sources
Figure 4 Primary Research Techniques
Figure 5 Key Executives Interviewed
Figure 6 Breakdown of Primary Interviews (Supply-side & Demand-Side)
Figure 7 Market Size Estimation
Figure 8 Global RWE Oncology Solutions Market, by Component, 2025 Vs. 2035 (USD Million)
Figure 9 Global RWE Oncology Solutions Market, by Application, 2025 Vs. 2035 (USD Million)
Figure 10 Global RWE Oncology Solutions Market, by End User, 2025 Vs. 2035 (USD Million)
Figure 11 RWE Oncology Solutions Market, by Geography
Figure 12 Market Dynamics
Figure 13 Number of People with Chronic Conditions in the U.S.
Figure 14 Percentage of Personalized Medicines Approved
Figure 15 Asia-Pacific: Percent Share of Global Clinical Trial Activity
Figure 16 Global RWE Oncology Solutions Market Size, by Component, 2025–2035 (USD Million)
Figure 17 U.S.: Number of E-Prescriptions
Figure 18 Global RWE Oncology Solutions Market Size, by Application, 2025–2035 (USD Million)
Figure 19 Estimated Number of New Cancer Cases, by Region, 2020–2040 (In Millions)
Figure 20 Global RWE Oncology Solutions Market Size, by End User, 2025–2035 (USD Million)
Figure 21 Proportion of the Pharmaceutical Pipeline Which is in Development for Cancer, 2010–2021
Figure 22 Global RWE Oncology Solutions Market, by Region, 2022–2029 (USD Million)
Figure 23 North America: RWE Oncology Solutions Market Snapshot
Figure 24 Europe: RWE Oncology Solutions Market Snapshot
Figure 25 France: Share of Population Aged 65 & Above
Figure 26 Italy: Share of Population Aged 65 Years & Above
Figure 27 Key Growth Strategies Adopted by Leading Players (2022–2025)
Figure 28 Real-world Evidence Oncology Solutions: Competitive Benchmarking
Figure 29 Market Share Analysis: Real-world Evidence Oncology Solutions Industry (2024)
Figure 30 IQVIA HOLDINGS INC.: Financial Overview
Figure 31 PPD, Inc.: Financial Overview
Figure 32 ICON plc: Financial Overview
Figure 33 IBM corporation: Financial Overview
Figure 34 UnitedHealth Group Incorporated: Financial Overview
Figure 35 Oracle Corporation: Financial Overview
Figure 36 Anthem, Inc.: Financial Overview
Figure 37 Clinigen Group plc: Financial Overview
Figure 38 Cognizant Technology Solutions Corporation: Financial Overview
Figure 39 PerkinElmer, Inc.: Financial Overview
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Oncology Information Systems Market - Global Opportunity Analysis and Industry Forecast (2025-2032)
Published Date: Jan-2025
Real-world Data (RWD) Market - Global Opportunity Analysis And Industry Forecast (2022-2029)
Published Date: Dec-2022
Oncology Ablation Market - Global Opportunity Analysis and Industry Forecast (2015-2020)
Published Date: Mar-2016
Microfluidic Immunoassay Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Jan-2024
U.S. Real-World Evidence Solutions Market - Opportunity Analysis And Industry Forecast (2022-2029)
Published Date: Oct-2022
